Cargando…
Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study
Background: Recent data have shown that the human papillomavirus (HPV) vaccine could impact on a decrease in high-grade cervical intraepithelial lesions (HSIL) in women who have undergone surgical treatment. This study aimed to evaluate the efficacy of human papilloma virus (HPV) vaccination against...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879017/ https://www.ncbi.nlm.nih.gov/pubmed/35214747 http://dx.doi.org/10.3390/vaccines10020288 |
_version_ | 1784658798056570880 |
---|---|
author | Casajuana-Pérez, Andrea Ramírez-Mena, Mar Ruipérez-Pacheco, Estefanía Gil-Prados, Inés García-Santos, Javier Bellón-del Amo, Mónica Hernández-Aguado, Juan J. de la Fuente-Valero, Jesus Zapardiel, Ignacio Coronado-Martín, Pluvio J. |
author_facet | Casajuana-Pérez, Andrea Ramírez-Mena, Mar Ruipérez-Pacheco, Estefanía Gil-Prados, Inés García-Santos, Javier Bellón-del Amo, Mónica Hernández-Aguado, Juan J. de la Fuente-Valero, Jesus Zapardiel, Ignacio Coronado-Martín, Pluvio J. |
author_sort | Casajuana-Pérez, Andrea |
collection | PubMed |
description | Background: Recent data have shown that the human papillomavirus (HPV) vaccine could impact on a decrease in high-grade cervical intraepithelial lesions (HSIL) in women who have undergone surgical treatment. This study aimed to evaluate the efficacy of human papilloma virus (HPV) vaccination against persistent/recurrent disease in patients undergoing conization for high-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia-grade 2-3 (HSIL/CIN 2-3). Methods: From January 2009 to March 2019, 563 patients with HSIL/CIN 2-3 underwent conization. The population was divided into two groups according to vaccination status: vaccinated-group (V-Group) and non-vaccinated-group (NV-Group). Bivalent or quadrivalent vaccines were administered indiscriminately. A follow-up was scheduled every 6–12 months according to clinical guidelines. The mean follow-up was 29.6 vs. 36.5 months in the V-group and NV-group, respectively. Results: 277 (49.2%) women were vaccinated, while 286 (50.8%) were not. Overall, persistent/recurrent HSIL/CIN 2-3 was presented by 12/277 (4.3%) women in the V-Group and 28/286 (9.8%) in the NV-Group (HR: 0.43, 95% Confidence interval 0.22–0.84, p = 0.014). Vaccination was associated with a 57% reduction in HSIL persistence/recurrence after treatment. When no disease was present in the first 6-month follow-up visit, persistence/recurrence rates were very low in both groups: 1.1% in the V-Group vs. 1.5% in the NV-Group (p > 0.05). The factor associated with a high-risk of HSIL persistence/recurrence was the presentation of a positive co-test in the first control after treatment (p < 0.001). Conclusions: Our results corroborate the benefit of HPV vaccination in woman treated for HSIL/CIN 2-3, showing a reduction of persistent/recurrent HSIL/CIN 2-3. |
format | Online Article Text |
id | pubmed-8879017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88790172022-02-26 Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study Casajuana-Pérez, Andrea Ramírez-Mena, Mar Ruipérez-Pacheco, Estefanía Gil-Prados, Inés García-Santos, Javier Bellón-del Amo, Mónica Hernández-Aguado, Juan J. de la Fuente-Valero, Jesus Zapardiel, Ignacio Coronado-Martín, Pluvio J. Vaccines (Basel) Article Background: Recent data have shown that the human papillomavirus (HPV) vaccine could impact on a decrease in high-grade cervical intraepithelial lesions (HSIL) in women who have undergone surgical treatment. This study aimed to evaluate the efficacy of human papilloma virus (HPV) vaccination against persistent/recurrent disease in patients undergoing conization for high-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia-grade 2-3 (HSIL/CIN 2-3). Methods: From January 2009 to March 2019, 563 patients with HSIL/CIN 2-3 underwent conization. The population was divided into two groups according to vaccination status: vaccinated-group (V-Group) and non-vaccinated-group (NV-Group). Bivalent or quadrivalent vaccines were administered indiscriminately. A follow-up was scheduled every 6–12 months according to clinical guidelines. The mean follow-up was 29.6 vs. 36.5 months in the V-group and NV-group, respectively. Results: 277 (49.2%) women were vaccinated, while 286 (50.8%) were not. Overall, persistent/recurrent HSIL/CIN 2-3 was presented by 12/277 (4.3%) women in the V-Group and 28/286 (9.8%) in the NV-Group (HR: 0.43, 95% Confidence interval 0.22–0.84, p = 0.014). Vaccination was associated with a 57% reduction in HSIL persistence/recurrence after treatment. When no disease was present in the first 6-month follow-up visit, persistence/recurrence rates were very low in both groups: 1.1% in the V-Group vs. 1.5% in the NV-Group (p > 0.05). The factor associated with a high-risk of HSIL persistence/recurrence was the presentation of a positive co-test in the first control after treatment (p < 0.001). Conclusions: Our results corroborate the benefit of HPV vaccination in woman treated for HSIL/CIN 2-3, showing a reduction of persistent/recurrent HSIL/CIN 2-3. MDPI 2022-02-14 /pmc/articles/PMC8879017/ /pubmed/35214747 http://dx.doi.org/10.3390/vaccines10020288 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Casajuana-Pérez, Andrea Ramírez-Mena, Mar Ruipérez-Pacheco, Estefanía Gil-Prados, Inés García-Santos, Javier Bellón-del Amo, Mónica Hernández-Aguado, Juan J. de la Fuente-Valero, Jesus Zapardiel, Ignacio Coronado-Martín, Pluvio J. Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study |
title | Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study |
title_full | Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study |
title_fullStr | Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study |
title_full_unstemmed | Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study |
title_short | Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study |
title_sort | effectiveness of prophylactic human papillomavirus vaccine in the prevention of recurrence in women conized for hsil/cin 2-3: the venus study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879017/ https://www.ncbi.nlm.nih.gov/pubmed/35214747 http://dx.doi.org/10.3390/vaccines10020288 |
work_keys_str_mv | AT casajuanaperezandrea effectivenessofprophylactichumanpapillomavirusvaccineinthepreventionofrecurrenceinwomenconizedforhsilcin23thevenusstudy AT ramirezmenamar effectivenessofprophylactichumanpapillomavirusvaccineinthepreventionofrecurrenceinwomenconizedforhsilcin23thevenusstudy AT ruiperezpachecoestefania effectivenessofprophylactichumanpapillomavirusvaccineinthepreventionofrecurrenceinwomenconizedforhsilcin23thevenusstudy AT gilpradosines effectivenessofprophylactichumanpapillomavirusvaccineinthepreventionofrecurrenceinwomenconizedforhsilcin23thevenusstudy AT garciasantosjavier effectivenessofprophylactichumanpapillomavirusvaccineinthepreventionofrecurrenceinwomenconizedforhsilcin23thevenusstudy AT bellondelamomonica effectivenessofprophylactichumanpapillomavirusvaccineinthepreventionofrecurrenceinwomenconizedforhsilcin23thevenusstudy AT hernandezaguadojuanj effectivenessofprophylactichumanpapillomavirusvaccineinthepreventionofrecurrenceinwomenconizedforhsilcin23thevenusstudy AT delafuentevalerojesus effectivenessofprophylactichumanpapillomavirusvaccineinthepreventionofrecurrenceinwomenconizedforhsilcin23thevenusstudy AT zapardielignacio effectivenessofprophylactichumanpapillomavirusvaccineinthepreventionofrecurrenceinwomenconizedforhsilcin23thevenusstudy AT coronadomartinpluvioj effectivenessofprophylactichumanpapillomavirusvaccineinthepreventionofrecurrenceinwomenconizedforhsilcin23thevenusstudy |